First Time Loading...

Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 11.91 USD 3.12%
Updated: May 14, 2024

Intrinsic Value

STOK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. [ Read More ]

The intrinsic value of one STOK stock under the Base Case scenario is 7.07 USD. Compared to the current market price of 11.91 USD, Stoke Therapeutics Inc is Overvalued by 41%.

Key Points:
STOK Intrinsic Value
Base Case
7.07 USD
Overvaluation 41%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Stoke Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling STOK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Stoke Therapeutics Inc

Provide an overview of the primary business activities
of Stoke Therapeutics Inc.

What unique competitive advantages
does Stoke Therapeutics Inc hold over its rivals?

What risks and challenges
does Stoke Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Stoke Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Stoke Therapeutics Inc.

Provide P/S
for Stoke Therapeutics Inc.

Provide P/E
for Stoke Therapeutics Inc.

Provide P/OCF
for Stoke Therapeutics Inc.

Provide P/FCFE
for Stoke Therapeutics Inc.

Provide P/B
for Stoke Therapeutics Inc.

Provide EV/S
for Stoke Therapeutics Inc.

Provide EV/GP
for Stoke Therapeutics Inc.

Provide EV/EBITDA
for Stoke Therapeutics Inc.

Provide EV/EBIT
for Stoke Therapeutics Inc.

Provide EV/OCF
for Stoke Therapeutics Inc.

Provide EV/FCFF
for Stoke Therapeutics Inc.

Provide EV/IC
for Stoke Therapeutics Inc.

Show me price targets
for Stoke Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Stoke Therapeutics Inc?

How accurate were the past Revenue estimates
for Stoke Therapeutics Inc?

What are the Net Income projections
for Stoke Therapeutics Inc?

How accurate were the past Net Income estimates
for Stoke Therapeutics Inc?

What are the EPS projections
for Stoke Therapeutics Inc?

How accurate were the past EPS estimates
for Stoke Therapeutics Inc?

What are the EBIT projections
for Stoke Therapeutics Inc?

How accurate were the past EBIT estimates
for Stoke Therapeutics Inc?

Compare the revenue forecasts
for Stoke Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Stoke Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Stoke Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Stoke Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Stoke Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Stoke Therapeutics Inc with its peers.

Analyze the financial leverage
of Stoke Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Stoke Therapeutics Inc.

Provide ROE
for Stoke Therapeutics Inc.

Provide ROA
for Stoke Therapeutics Inc.

Provide ROIC
for Stoke Therapeutics Inc.

Provide ROCE
for Stoke Therapeutics Inc.

Provide Gross Margin
for Stoke Therapeutics Inc.

Provide Operating Margin
for Stoke Therapeutics Inc.

Provide Net Margin
for Stoke Therapeutics Inc.

Provide FCF Margin
for Stoke Therapeutics Inc.

Show all solvency ratios
for Stoke Therapeutics Inc.

Provide D/E Ratio
for Stoke Therapeutics Inc.

Provide D/A Ratio
for Stoke Therapeutics Inc.

Provide Interest Coverage Ratio
for Stoke Therapeutics Inc.

Provide Altman Z-Score Ratio
for Stoke Therapeutics Inc.

Provide Quick Ratio
for Stoke Therapeutics Inc.

Provide Current Ratio
for Stoke Therapeutics Inc.

Provide Cash Ratio
for Stoke Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Stoke Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Stoke Therapeutics Inc?

What is the current Free Cash Flow
of Stoke Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Stoke Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Stoke Therapeutics Inc

Current Assets 193.3m
Cash & Short-Term Investments 178.6m
Receivables 11k
Other Current Assets 14.7m
Non-Current Assets 11.9m
PP&E 11.3m
Other Non-Current Assets 569k
Current Liabilities 35.6m
Accounts Payable 2.1m
Accrued Liabilities 11.6m
Other Current Liabilities 21.9m
Non-Current Liabilities 29.3m
Other Non-Current Liabilities 29.3m
Efficiency

Earnings Waterfall
Stoke Therapeutics Inc

Revenue
7.8m USD
Operating Expenses
-126.3m USD
Operating Income
-118.4m USD
Other Expenses
9.9m USD
Net Income
-108.5m USD

Free Cash Flow Analysis
Stoke Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

STOK Profitability Score
Profitability Due Diligence

Stoke Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Negative 1-Year Revenue Growth
Declining ROE
21/100
Profitability
Score

Stoke Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

STOK Solvency Score
Solvency Due Diligence

Stoke Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
65/100
Solvency
Score

Stoke Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

STOK Price Targets Summary
Stoke Therapeutics Inc

Wall Street analysts forecast STOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STOK is 23.97 USD with a low forecast of 17.17 USD and a high forecast of 36.75 USD.

Lowest
Price Target
17.17 USD
44% Upside
Average
Price Target
23.97 USD
101% Upside
Highest
Price Target
36.75 USD
209% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

STOK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

STOK Price
Stoke Therapeutics Inc

1M 1M
-2%
6M 6M
+153%
1Y 1Y
+1%
3Y 3Y
-67%
5Y 5Y
-53%
10Y 10Y
-53%
Annual Price Range
11.91
52w Low
3.37
52w High
14.17
Price Metrics
Average Annual Return 0.43%
Standard Deviation of Annual Returns 84.52%
Max Drawdown -95%
Shares Statistics
Market Capitalization 620.7m USD
Shares Outstanding 52 117 500
Percentage of Shares Shorted 24%

STOK Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

620.7m USD

Dividend Yield

0%

Description

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

Contact

MASSACHUSETTS
Bedford
3 Preston Ct
+17814308200.0
https://www.stoketherapeutics.com/

IPO

2019-06-19

Employees

102

Officers

CEO & Director
Dr. Edward M. Kaye M.D., Ph.D.
Co-Founder & Independent Director
Dr. Adrian R. Krainer Ph.D.
Chief Financial Officer
Mr. Stephen J. Tulipano CPA, MBA
Chief Medical Officer
Dr. Barry S. Ticho FACC, M.D., Ph.D.
Co-Founder & Group VP of Discovery Research
Ms. Isabel Aznarez Ph.D.
COO & Chief Business Officer
Dr. Huw M. Nash Ph.D.
Show More
Head of Investor Relations
Mr. Eric Rojas
Corporate Secretary & General Counsel
Mr. Jonathan Allan J.D.
Chief Communications Officer
Ms. Dawn Kalmar
Chief Human Resources Officer
Ms. Joan Wood
Show Less

See Also

Discover More
What is the Intrinsic Value of one STOK stock?

The intrinsic value of one STOK stock under the Base Case scenario is 7.07 USD.

Is STOK stock undervalued or overvalued?

Compared to the current market price of 11.91 USD, Stoke Therapeutics Inc is Overvalued by 41%.